ConTIPI Medical, a leader in non-surgical solutions for pelvic floor dysfunctions, has chosen EVERSANA to spearhead the U.S. commercialization of its innovative ProVate device. This partnership aims to provide a new, non-surgical option for the 57 million American women suffering from pelvic organ prolapse (POP).
ProVate, a ready-to-use, disposable device, empowers women to manage POP at home. The device, which resembles a menstrual tampon applicator, offers six sizes and can be used for up to seven days. Women can easily insert and remove ProVate, giving them control over their condition.
EVERSANA will handle all aspects of the commercialization process, including pricing, reimbursement, market access, pharmacovigilance, medical communications, sales, regulatory, marketing, and commercial operations. Jim Lang, CEO of EVERSANA, expressed excitement about the partnership, highlighting the company’s commitment to bringing innovative treatment options to patients.
Dr. Elan Ziv, CEO and Medical Director of ConTIPI Medical, emphasized the importance of a commercialization partner who understands their mission and vision. He believes EVERSANA’s proven success in product commercialization and patient adoption makes them the ideal partner.
ProVate has received FDA clearance for marketing in the U.S. and bears the CE mark for marketing in Europe. Clinicians will begin prescribing ProVate in September 2024.
More info at eversana.com
